2026-01-24 - Analysis Report
**Financial Report for Amgen Inc. (AMGN)**

**Company Overview**
Amgen is a biotechnology company that develops and manufactures human therapeutics in the areas of cardiovascular disease, cancer, and other diseases.

**Investment Comparison**

- **Stock Ticker:** AMGN
- **Comparison Index:** S&P 500 (VOO)
- **Cumulative Return (AMGN):** 90.41%
- **Cumulative Return (VOO):** 126.41%
- **Divergence:** -36.00, relative divergence: 34.30%
The current stock (AMGN) has a lower cumulative return compared to the S&P 500. However, the relative divergence is within 34.30% of the maximum-minimum fluctuation range.

**Performance Analysis**

| Year       | CAGR | MDD  | Alpha | Beta |
|------------|------|------|-------|-------|
| 2016-2018  | 23.0% | 16.0% | 11.0% | 1.1    |
| 2017-2019  | 45.0% | 12.4% | 19.0% | 0.9    |
| 2018-2020  | 18.0% | 21.7% | -6.0% | 0.8    |
| 2019-2021  | 16.0% | 21.7% | -50.0% | 0.8    |
| 2020-2022  | 20.0% | 19.6% | 13.0% | 0.6    |
| 2021-2023  | 23.0% | 20.4% | 2.0% | 0.4    |
| 2022-2024  | 15.0% | 21.4% | -15.0% | 0.4    |
| 2023-2025  | 37.0% | 21.4% | -38.0% | 0.5    |
The company's performance has fluctuated across various years. The CAGR and MDD have shown varying degrees of growth and decline.

**Stock Price Analysis**

- **Close:** $344.75
- **Last-Market:** {'price': 344.75, 'previousClose': 347.07, 'change': -0.67}
- **5-day SMA:** $339.37
- **20-day SMA:** $331.73
- **60-day SMA:** $327.76
The 5-day SMA is the closest to the current price, indicating a short-term decline in the stock price.

**Indicators and Risk Analysis**

- **Market Risk Indicator (MRI):** 0.70
- **RSI:** 62.17
- **PPO:** 0.54
- **Hybrid Signal:** Buy (Cash 0%)
- **Risk Level:** Medium
- **MRI:** High Investment Recommended
- **Recent (20 days) Relative Divergence Change:** 9.50 (+)
- **7-day Rank Change:** 66 (+)
- **7-day Dynamic Expected Return Change:** -28.40 (-)
- **Expected Return (%):** -30.50%
The current market risk indicator suggests a medium investment, while the RSI and PPO indicators do not show significant divergences. However, the recent relative divergence change is improving, and the 7-day rank change is up. The expected return is negative, indicating a potential for long-term decline in the stock price.

**Analyst Opinions**

**Analyst Consensus:**
- **Key:** Buy
- **Mean (1=StrongBuy~5=Sell):** 2.41 (~Buy)
- **Opinions:** 27
- **Target Price (avg/high/low):** 331.59 / 425.00 / 180.00

The analyst consensus suggests a buy with a mean rating of 2.41 and a target price range of 331.59 to 425.00.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-11-05 | 5.98 | 9.56 B$ |
| 2025-08-06 | 2.66 | 9.18 B$ |
| 2025-05-02 | 3.22 | 8.15 B$ |
| 2024-10-31 | 5.27 | 8.50 B$ |

The quarterly earnings per share (EPS) has ranged from 2.66 to 5.98, and the revenue has ranged from 8.15 B$ to 9.56 B$. The revenue has generally increased over time.

**Financial Information**

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

The profit margin has ranged from 61.07% to 67.75%. The revenue has generally increased over time.

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

The return on equity (ROE) has ranged from 10.67% to 37.60%. The equity has generally increased over time.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.